Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC Appoints Larry Bullock as Chief Financial Officer
Seasoned finance executive brings more than two decades of biotech experience
View HTML
Toggle Summary AGTC Awarded Additional Grant from the National Eye Institute
Funding will support expanded development of AGTC's gene therapy treatment for achromatopsia, a rare eye disease
View HTML
Toggle Summary AGTC Scientific Founders William W. Hauswirth and R. Jude Samulski Receive Pioneer Awards for Seminal Work in Gene and Cell Therapy
Blue Ribbon Panel Commissioned by Peer-reviewed Journal Human Gene Therapy Identifies Top 12 Pioneers in Field
View HTML
Toggle Summary AGTC and the University of Massachusetts Medical School Report Promising Phase II Gene Therapy Clinical Data
Study published in the Journal of Clinical Investigation shows sustained therapeutic protein expression detected for up to one year following a single dose
View HTML
Toggle Summary AGTC Expands Management Team with Two Key Hires
AGTC Expands Management Team with Two Key Hires November 5, 2013 - AGTC, a clinical stage biotechnology company announced that the company has hired two new management team members, Daniel L. Menichella and Frank Sprecher. Both bring a wealth of previous leadership experience in the pharmaceutical
View HTML
Toggle Summary Researchers see gene-therapy grant improving vision
Researchers see gene-therapy grant improving vision July 24, 2013 - The University of Florida’s ophthalmology department, together with gene therapy company AGTC in Alachua, received an $8.4 million grant from the National Eye Institute at the National Institutes of Health to study gene therapy for
View HTML
Toggle Summary The University of Florida and AGTC Secure $8.4M Grant to Study Rare Eye Disease
Funds will be used to develop a gene therapy treatment for Achromatopsia in both animal models and human clinical trials
View HTML
Toggle Summary The Alpha-1 Project announces first investment in potential treatment for Alpha-1 Antitrypsin Deficiency, major emphysema genetic risk factor
Applied Genetic Technologies Corporation to conduct clinical trials
View HTML
Toggle Summary AGTC Secures $37.5 Million Series B Funding
Clinical stage gene therapy company will use financing, led by Alta Partners and S.R. One, to fund studies for the treatments of rare human diseases
View HTML
Toggle Summary AGTC Receives Grant from the Foundation Fighting Blindness for Pre-Clinical Study of Gene Therapy for Eye Disease
Pre-clinical trial in animal models tests ability to deliver sustainable treatment in patients with X-Linked Retinoschisis (XLRS) using proprietary AAV gene delivery technology.
View HTML
Visionary science for life changing cures.